胸腔病例（三六一）肺高壓

10.6666/ClinMed.201912_84(6).0139

李彥融；陳威志；張西川

肺動脈高壓（pulmonary arterial hypertension） ； 肺高壓（pulmonary hypertension）

臨床醫學月刊

84卷6期（2019 / 12 / 27）

842 - 846

繁體中文

肺動脈高壓為一罕見，且症狀無特異性，可由多種原因造成肺動脈壓力上升的疾病。本文就一病患因活動性呼吸喘入院，進而診斷肺動脈高壓之診斷及治療過程作為引子，引申介紹肺高壓、肺動脈高壓相關診斷、治療。肺高壓因症狀不明顯，因此時常需耗費較多時間才能夠獲得正確診斷，且後續相關診斷亦須轉介至肺高壓專業院所進行一系列的病因釐清、診斷、評估預後、治療。因此醫師應將此診斷列入考量，若有懷疑，須及早進行相關檢查及轉至專門院所，進一步診斷、治療，期以改善患者症狀及預後。

1. Braganza, M,Shaw, J,Solverson, K(2019).A Prospective Evaluation of the Diagnostic Accuracy of thePhysical Examination for Pulmonary Hypertension.Chest,155,982-990.
2. Escribano-Subias, P,Blanco, I,LópezMeseguer, M(2012).Survival in pulmonary hypertension in Spain: insights from the Spanish registry.Eur Respir J,40,596-603.
3. Ferrara, F,Zhou, X,Gargani, L(2019).Echocardiography in Pulmona ryArterial Hypertension.Curr Cardiol Rep,21,22.
4. Frost, A,Badesch, D,Gibbs, JSR(2019).Diagnosis of pulmonary hypertension.Eur Respir,53,1801904.
5. Galiè, N,Humbert, M,Vachiery, J-L(2015).ESC/ERS guidelines for the diagnosis and treatment of pulmonaryhypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology(ESC)and the European Respiratory Society(ERS): endorsed by: Association for European Paediatric and Congenital Cardiology(AEPC), International Society for Heart and Lung Transplantation(ISHLT).Eur Heart J,37,67-119.
6. Galié, N,Manes, A,Branzi, AJCr(2004).The endothelin system in pulmonary arterial hypertension.Cardiovasc Res,61,227-237.
7. Giaid, A,Yanagisawa, M,Langleben, D(1993).Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.N Engl J Med,328,1732-1739.
8. Girerd, B,Montani, D,Eyries, M(2010).Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension.Respir Res,11,73.
9. Hellenkamp, K,Unsold, B,Mushemi-Blake, S(2018).Echocardiographic Estimation of Mean Pulmonary Artery Pressure: A Comparison of Different Approaches to Assign the Likelihood of Pulmonary Hypertension.J Am Soc Echocardiogr,31,89-98.
10. Humbert, M,Guignabert, C,Bonnet, S(2019).Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives.Eur Respir J,53,1801887.
11. Humbert, M,Sitbon, O,Chaouat, A(2006).Pulmonary arterial hypertension in France: results from a nationalregistry.Am J Respir Crit Care Med,173,1023-1030.
12. Moreira, EM,Gall, H,Leening, MJ(2015).Prevalence of Pulmonary Hypertension in the General Population: The Rotterdam Study.PloS One,10,e0130072.
13. Peacock, A,Murphy, N,McMurray, J(2007).An epidemiological study of pulmonary arterial hypertension.Eur Respir J,30,104-109.
14. Rich, S,Kaufmann, E,Levy, PSJNEJoM(1992).The effect of high doses of calciumchannel blockers on survival in primary pulmonary hypertension.N Engl J Med,327,76-81.
15. Simonneau, G,Montani, D,Celermajer, DS(2019).Haemodynamic definitions and updated clinical classification of pulmonary hypertension.Eu Respir J,53,1801913.
16. Sitbon, O,Gomberg-Maitland, M,Granton, J(2019).Clinical trial designand new therapies for pulmonary arterial hypertension.Eur Respir J,53,1801908.
17. Sitbon, O,Humbert, M,Jaïs, X(2005).Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.Circulation,111,3105-3111.
18. Stewart, DJ,Levy, RD,Cernacek, P(1991).Increased plasma endothelin-1 in pulmonary hypertension: marker ormediator of disease?.Ann Intern Med,114,464-469.
19. Tantini, B,Manes, A,Fiumana, E(2005).Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells.Basic Res Cardiol,100,131-138.
20. Ventetuolo, CE,Praestgaard, A,Palevsky, HI(2014).Sex and haemodynamics in pulmonary arterial hypertension.Eur Respir J,43,523-530.
21. Wharton, J,Strange, JW,Møller, GM(2005).Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.Am J Respir Crit Care Med,172,105-113.